7-Isopropyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline | 1268144-17-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 7-Isopropyl-4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 4,4-dimethyl-7-propan-2-yl-2,3-dihydro-1H-isoquinoline
• CAS: 1268144-17-7
• 化学式: C₁₄H₂₁N
• 分子量: 203.32
• InChiKey: JUSDECVWCCKZFX-UHFFFAOYSA-N

物化性质

• 沸点：
  283.6±9.0 °C(Predicted)
• 密度：
  0.920±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：giraFpharma LLC

  公开号：US20190106427A1

  公开（公告）日：2019-04-11

  Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Wee1抑制剂的杂环化合物。这些化合物可能被用作治疗剂，用于治疗疾病，并且可能在肿瘤学中发挥特定作用。
• Heterocyclic compounds and uses thereof
  申请人：NUVATION BIO INC.

  公开号：US10807994B2

  公开（公告）日：2020-10-20

  Heterocyclic compounds of Formula (I): as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  式 (I) 的杂环化合物： 提供了作为 Wee1 抑制剂的杂环化合物。这些化合物可用作治疗疾病的药物，尤其可用于肿瘤学。
• Heterocyclic compounds as kinase inhibitors
  申请人：NUVATION BIO INC.

  公开号：US11174252B2

  公开（公告）日：2021-11-16

  Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为 CDK4 或 CDK6 或其他 CDK 抑制剂的式 (J) 的杂环化合物。这些化合物可用作治疗疾病的药物，尤其可用于肿瘤学。
• Substituted pyrazolo[3,4-d]pyrimidines as Wee1 inhibitors
  申请人：NUVATION BIO INC.

  公开号：US11332473B2

  公开（公告）日：2022-05-17

  This invention provides for substituted pyrazolo[3,4-d]pyrimidine compounds of the Formula (I): as Wee1 inhibitors. The substituted pyrazolo[3,4-d]pyrimidine compounds may find use as therapeutic agents for the treatment of diseases. The substituted pyrazolo[3,4-d]pyrimidine compounds may also find particular use in oncology.

  本发明提供了式 (I) 的取代吡唑并[3,4-d]嘧啶化合物： 作为 Wee1 抑制剂。取代的吡唑并[3,4-d]嘧啶化合物可用作治疗疾病的药物。取代的吡唑并[3,4-d]嘧啶化合物还可用于肿瘤学。
• HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
  申请人：GIRAFPHARMA LLC

  公开号：US20190248774A1

  公开（公告）日：2019-08-15

  Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.